NOVEMBER 18, 2015
Glytec Receives Approval from The USPTO on Another Patent
Second allowance covers its unique insulin administration method.
Waltham, MA — Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application directed toward a method of administering insulin proven to improve patient outcomes compared to antiquated paper protocols. The method entails selecting a precise subcutaneous insulin treatment for each patient based on blood glucose measurements and other patient information, and administering the selected treatment.
“This particular Notice of Allowance serves as further corroboration of the uniqueness of many foundational aspects of our integrated hospital-to-home glycemic management solution, which has been accruing extraordinary results for providers and patients. There have been 47 studies published to date concerning our system and 28 more studies are in process, including a just completed remarkable 60,000 plus patient study focused on hypoglycemia to be published next year, collectively validating the overwhelming impact of our patient-centered technologies on quality and cost,” said Bob Leonard, President & CEO of Glytec.
The subcutaneous insulin treatment covers several different insulin delivery modules, including one or more of a standard subcutaneous module, a subcutaneous module without meal boluses, a meal-by-meal subcutaneous module without carbohydrate counting, a meal-by-meal subcutaneous module with carbohydrate counting, and a subcutaneous module for people without diabetes.
The standard subcutaneous program includes calculating an individualized insulin dose based on a patient’s blood glucose values, time of day, as well as other attributes specific to a particular blood glucose measurement. Methods to calculate personalized correction doses of insulin are also described.
“Nearly 40% of patients admitted to acute care hospitals in the United States experience hyperglycemia and some 10% hypoglycemia, and there are hundreds of thousands of emergency room visits and hospitalizations each year related to glucose control that could be avoided. Our solutions are pointed at a very big problem, both in and out of the hospital,” said Glytec’s Chief Medical Officer, Andrew S. Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC. “Providers and patients have long experienced the ineffectiveness of sliding scale and paper protocols. Our unique insulin administration method and glycemic management decision support system enables them to take advantage of the growing availability of actionable data and stage appropriate interventions safely, effectively and efficiently across the continuum of care.”
Further patent applications covering other technologies of the company are currently pending before the U.S. Patent and Trademark Office. Rhinehart added, “We’re of course pleased with the continued expansion of our intellectual property portfolio, as it reflects years of innovation, Glytec’s leadership role in the therapy management software realm and our focus on delivering solutions that help providers, payers and potentially millions of patients realize the improvement in outcomes that are so badly needed.”
Founded in 2006, Glytec is a rapidly growing digital health company specializing in integrated inpatient and outpatient technologies for diabetes care, with the mission of improving medication management and glycemic control across the continuum. eGMS®, Glytec’s integrated glycemic management decision support system, enables providers, payers and patients to significantly reduce the frequency, risks and costs of hyperglycemia and hypoglycemia. The cloud based, modular eGMS® centers on the Glucommander suite of FDA-cleared, complex dosing algorithms for IV, subcutaneous and pediatric dosing. The management of patients requiring insulin therapy is further enabled by seamless EHR and connected device integration (SmartClick) and robust analytics (Glucometrics) and surveillance (GlucoSurveillance) capabilities. eGMS® interventional clinical decision support tools allow providers to standardize processes and personalize treatment across all areas of care, and is proven to result in significant improvements in clinical and financial outcomes versus traditional methods. For more information, please visit www.glytecsystems.com.